IMAC Holdings launched Ignite Proteomics, focusing on protein-level insights to personalize cancer treatments more effectively.
Quiver AI Summary
IMAC Holdings, Inc. has launched Ignite Proteomics LLC, a new subsidiary focused on enhancing cancer treatment personalization through protein-level analysis. This initiative aims to improve the selection of effective therapies, particularly for breast cancer, by addressing the limitations of existing genomic tests, which only provide a genetic blueprint rather than real-time insights into tumor behavior. Ignite’s multi-protein test measures various proteins in a single sample to better inform treatment decisions, potentially revolutionizing the multi-billion-dollar genomic testing market. The test, developed in collaboration with leading cancer centers, seeks to help physicians avoid ineffective treatment strategies and improve patient outcomes by focusing on proteins that drive cancer responses, particularly in the context of advanced therapies like antibody-drug conjugates and immunotherapies. IMAC Holdings plans to change its name to IMAC Holdings, Inc, DBA Ignite Sciences, Inc. as part of this initiative.
Potential Positives
- IMAC Holdings has launched Ignite Proteomics, a new subsidiary focused on protein-level cancer treatment analysis, addressing a significant gap in personalized cancer therapies.
- Ignite's multi-protein test offers a unique approach that could disrupt the multi-billion-dollar genomic testing market, with an available market of $600M for its current indications.
- The test’s ability to measure multiple critical proteins can enhance treatment decision-making, potentially improving patient outcomes and reducing trial-and-error treatment delays.
- Active collaborations with leading cancer centers could expand Ignite’s clinical evidence and integration into routine care, positioning the company as a leader in personalized oncology.
Potential Negatives
- IMAC Holdings is entering a highly competitive field dominated by established players in genomic testing, which may lead to market challenges and funding pressures.
- The announcement does not provide significant data on clinical performance or outcomes of the new proteomics testing, potentially raising skepticism about its viability.
- Changing the company name could confuse current stakeholders and customers, leading to potential brand identity issues during the transition to Ignite Sciences, Inc.
FAQ
What is Ignite Proteomics LLC?
Ignite Proteomics LLC is a subsidiary of IMAC Holdings focused on protein-level analysis for personalized cancer treatment guidance.
How does Ignite's testing differ from genomic tests?
Ignite's multi-protein test provides real-time insights into tumor behavior, while genomics only reveal genetic potential.
Why are proteins important in cancer therapy?
Proteins drive cell behavior and can better predict how a tumor responds to specific cancer treatments compared to genomic testing.
What types of cancer treatments can Ignite help identify?
Ignite's tests assist in selecting therapies, including antibody-drug conjugates (ADCs) and immunotherapies, for various cancer types.
How does Ignite plan to grow within oncology?
Ignite is collaborating with leading cancer centers to expand clinical evidence and integrate its tests into routine cancer care.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BACK Hedge Fund Activity
We have seen 5 institutional investors add shares of $BACK stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KESTRA ADVISORY SERVICES, LLC removed 44,395 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $49,722
- CITADEL ADVISORS LLC added 17,363 shares (+inf%) to their portfolio in Q3 2024, for an estimated $19,446
- WALLEYE CAPITAL LLC removed 13,831 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $15,490
- GEODE CAPITAL MANAGEMENT, LLC added 11,642 shares (+inf%) to their portfolio in Q3 2024, for an estimated $13,039
- TWO SIGMA SECURITIES, LLC added 11,545 shares (+inf%) to their portfolio in Q3 2024, for an estimated $12,930
- UBS GROUP AG removed 4,917 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $5,507
- TOWER RESEARCH CAPITAL LLC (TRC) added 592 shares (+15.9%) to their portfolio in Q3 2024, for an estimated $663
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Nashville, TN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”) has launched Ignite Proteomics LLC (“Ignite”), its new subsidiary dedicated to helping doctors select the most effective cancer treatments based on protein-level insights. This move addresses a growing need for better, faster ways to personalize therapy in breast cancer and beyond.
Why Proteins Matter – Beyond Genomics
Although genomics (gene-based) testing has become common, patients and providers find it has not fully delivered on the promise of personalized care. One reason is that genetics only reveal potential – the blueprint of the disease – while proteins show what is happening inside cancer cells right now. Ignite is poised to disrupt the multi-billion-dollar genomic testing market. The available market in the test’s current clinically approved indication is $600M.
Proteins drive cell behavior and are the direct targets of many new cancer drugs, especially antibody-drug conjugates (ADCs) and immunotherapies. Without measuring key proteins, standard genomic tests can miss crucial signals that predict how a tumor will respond – or fail to respond – to treatment.
Ignite’s multi-protein test addresses this gap. By measuring a range of proteins in a single sample, it offers a richer view of a tumor’s activity and vulnerability to specific therapies. Several of the assay’s important novel biomarkers are protected by licensed patents, ensuring a unique platform for guiding advanced treatment choices.
“Gene tests alone don’t tell us enough about how to pick the right therapies,” said Faith Zaslavsky, CEO of IMAC Holdings and Ignite Proteomics. “Proteins are what guide a cancer’s behavior and drug response. Our test focuses on these real-time signals, so doctors can better select complex treatments right from the start.”
A Better Approach to Modern Cancer Treatments
Today’s advanced therapies—from new ADCs to immunotherapies—are more complex than traditional chemo. Standard “one-marker” tests often fail to identify which patients can truly benefit. Ignite’s test reviews multiple critical proteins at once, helping physicians:
- Spot lower levels of drug targets that standard methods might overlook.
- Determine whether an immunotherapy is likely to work—or if a patient would do better with another option.
- Avoid the costly and time-consuming trial-and-error approach that can delay effective treatment.
Looking Ahead: Partnerships & Growth
- Active Collaborations: Ignite is working with leading cancer centers to expand clinical evidence and incorporate its test into more routine care.
- Expanding Impact: The test’s ability to measure what genes alone cannot detect is expected to fill a major gap in personalized oncology.
- Focus on ADCs & Immunotherapy: With more complex drugs rolling out each year, physicians need deeper insights into a tumor’s real-time behavior—and that is exactly where Ignite’s protein-level approach excels.
- Standard of care: Ignite’s protein analysis has generated and is expanding clinical data needed to be included in treatment guidelines for breast cancer.
About IMAC Holdings, Inc.
IMAC Holdings, Inc. strives to improve patient outcomes through innovative healthcare solutions. By combining strategic acquisitions and innovative technologies, IMAC Holdings remains committed to advancing personalized medicine. IMAC Holdings has begun the process to change its name and will soon be shown as IMAC Holdings, Inc, DBA Ignite Sciences, Inc.
About Ignite Proteomics
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, specializes in protein-based analysis for cancer treatment guidance. Operating under a CLIA-accredited lab, Ignite provides a single test covering multiple markers to help doctors pinpoint the most suitable therapies, bridging the gap that gene-focused methods leave behind. Several key markers in the assay are protected by licensed patents.
Forward-Looking Statements
This press release contains statements that involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ. Readers are cautioned not to place undue reliance on these statements. For more information, please review the Company’s SEC filings.
Contact Information:
[email protected]